Objectives. Recent genome-wide association and functional studies have shown that the ABCG2 gene encodes for a urate transporter, and a common causal ABCG2 variant, rs2231142, leads to elevated uric acid levels and prevalent gout among Whites and Blacks. We examined whether this finding is observed in a Japanese population, since Asians have a high reported prevalence of the T-risk allele.
Introduction
Hyperuricaemia is a key risk factor for gout and has been described as associated with cardiovascular risk factors and diseases such as hypertension, diabetes, metabolic syndrome, stroke and coronary heart disease [1] . Recently, Dehghan et al. [2] conducted population-based genome-wide association studies and identified three genetic loci associated with increased serum uric acid concentration and prevalence of gout. The most significant association at one of the loci was observed for a missense single nucleotide polymorphism (SNP), rs2231142 in the ABCG2 gene. Each copy of the T allele at rs2231142 was associated with gout in both White [odds ratio (OR) 1.74; 95% CI 1.51, 1 .99] and Black (OR 1.71; 95% CI 1.06, 2.77) study participants. In a subsequent functional study, it was shown that ABCG2 is a urate transporter that mediates urate excretion in the kidney, and that the rs2231142 T allele encodes for a reduced-function mutation leading to reduced ability to excrete uric acid [3] . Interestingly, the risk allele is three times more frequent in the Japanese compared with the European-ancestry HapMap samples, but, so far, the association of this locus with serum uric acid or prevalent gout has rarely been examined in races/ethnicities other than Whites and Blacks. We therefore examined whether this association replicates in Japan, where prevalence of gout has rapidly increased since the 1960s [4] .
Methods

Ethics statement
This study was approved by the Institutional Review Board of the University of Tsukuba. All participants whose data were analysed in this study provided written informed consent for the collection of samples and subsequent analysis.
Study population and measurement of exposure and outcomes
The Circulatory Risk in Communities Study (CIRCS) is an ongoing dynamic community cohort study involving five communities in Japan. The rs2231142 variant in ABCG2 (Q141K) was genotyped in participants in community surveys in 2001 in Kyowa and in 2003 in Ikawa, as a part of the CIRCS. A total of 4418 participants, aged 540 years, in these Japanese farming communities provided written informed consent for DNA analysis (consent rate = 98%). The genotype was determined by the intercalator-mediated fluorescence resonance energy transfer probe method using Taq DNA polymerase (rTaq; Toyobo, Osaka, Japan) at the Tsuruga Laboratory of Toyobo Gene Analysis Co. Ltd (Osaka, Japan). Detailed methods for genotyping were described elsewhere [5] . The designed probe was 5 0 -AGAGAAAACTTACAGTTCTCAGCAG-3 0 with Texas Red-end, specific to G allele. Serum uric acid and other health information were also collected [6] . Uric acid was measured by the uricase/peroxidase methods at the Osaka Medical Center for Health Science and Promotion (Osaka, Japan). History/treatment of gout and treatment of hyperuricaemia were ascertained faceto-face by trained interviewers. Gout was defined if participants answered that they had experienced gout, had been diagnosed as having gout by physicians or were receiving treatment for gout. Hyperuricaemia was defined if they had a uric acid concentration of 5415.9 mmol/l (7.0 mg/dl) based on blood testing, or answered that they were under treatment for hyperuricaemia at interview. If they had a uric acid concentration of 5415.9 mmol/l, based on records from previous annual checkups, the interview confirmed whether or not the participants were now receiving treatment for hyperuricaemia. We excluded persons with unsuccessful genotyping (n = 1), missing DNA (n = 70) and missing uric acid data (n = 424). Ultimately, 3923 participants were included in this study.
Statistical analyses
We used analysis of covariance for calculation of multivariable-adjusted mean values of serum uric acid across genotypes, and multivariable-adjusted logistic regression models for calculation of ORs and 95% CIs. We evaluated an additive genetic model (i.e. genotypes were coded as 0 for GG, 1 for TG and 2 for TT) and also compared the TG and TT genotypes separately with the reference genotype GG: the Hosmer-Lemeshow test showed that the logistic regression models fit the data well for these analyses. To test for significance, we assumed an additive genetic model analogous to previously reported analyses [2] . We did not find a significant difference in the variance in uric acid concentration across the genotype groups using the Levene's test (P = 0.35). Although the distribution of uric acid concentration was not statistically normal (Kolmogorov-Smirnov P < 0.01), we did not log-transform the values to permit comparability with the discovery report [2] . The distribution was virtually quasi-normal, and the logtransformation did not improve the normality. Covariates were selected to match covariates used in the discovery report [2] , i.e. age, sex, BMI (kg/m 2 ), alcohol consumption (g/day), hypertension treatment and community. Population attributable risk fraction (%), which represents the percentage of gout that might be due to rs2231142, was calculated as [(P TG ) (PR TG À 1) + (P TT ) (PR TT À 1)]/ [1 + (P TG ) (PR TG À 1) + (P TT ) (PR TT À 1)] Â 100, where P TG or P TT corresponds to the proportion of individuals exposed to TG or TT genotype among those without gout, and PR TG or PR TT is the respective unadjusted prevalence ratio of gout/hyperuricaemia. We used SAS version 9.1.3 Service Pack 4 (SAS Institute Inc., Cary, NC, USA) for analyses. All probability values for statistical tests were two-tailed, and P < 0.05 was regarded as statistically significant.
Results
The genotype distribution conformed to Hardy-Weinberg equilibrium (P 5 0.54). The frequency of the risk allele (T) was 31% in this Japanese sample, much higher than that reported for Whites (11-12%) and Blacks (3%) by Dehghan et al. [2] (Table 1) . Conversely, mean uric acid concentration was much lower in the Japanese (282.1 mmol/l) than reported for Whites (315.2-350.9 mmol/l) and Blacks (374.7 mmol/l). Age, BMI, alcohol drinking and anti-hypertensive medication use did not differ substantially across the three genotype categories ( Table 2) .
As shown in Table 3 , mean uric acid concentration was 7-9 mmol/l higher for TG and TT than GG carriers after adjustment for age, sex, community, BMI, alcohol consumption and anti-hypertensive treatment (P-additive = 0.0006). While this association was linear in women, uric acid levels were lower among TT than TG carriers in men. The R 2 for uric acid concentration was 0.279 in this multivariate model without ABCG2 and 0.281 with ABCG2 genotype.
Compared with the GG genotype, the multivariableadjusted OR of gout was 1.37 (95% CI 0.68, 2.76) for TG and 4.37 (95% CI 1.98, 9.62) for TT carriers (P-additive = 0.001; OR 2.03; 95% CI 1.33, 3.12 per T allele) ( Table 3) . When we combined hyperuricaemia (defined as hyperuricaemia treatment and/or uric acid 5415.9 mmol/l) with gout as one outcome, the respective ORs were 1.40 (95% CI 1.04, 1.87) for TG and 1.88 (95% CI 1.23, 2.89) for TT carriers (P-additive = 0.002; OR 1.38; 95% CI 1.13, 1.68 per T allele). Of note, the recessive genetic model provided a better fit than the additive model for gout as indicated by a lower Akaike's Information Criterion (P-recessive = 0.0002). The population attributable fraction for rs2231142 was 29% for gout and 19% for gout and/or hyperuricaemia.
Discussion
Our study confirms the results by Dehghan et al. [2] , a subsequent meta-analysis of European ancestry subjects [7] , Gout was defined as a history of symptoms and/or past or present treatment of gout;
d Hyperuricaemia was defined as uric acid of 5415.9 mmol/l (7.0 mg/dl) and/or treatment of hyperuricaemia. and some other case-control studies including those from Japan [8] and China [9] , reporting an association of rs2231142 with serum uric acid levels and gout. In addition, it is the first study of rs2231142 in a communitybased setting of Asian ancestry, a Japanese sample. Our finding is consistent with the recently established causality of the rs2231142 variant [3, 8] .
Although the prevalence of the risk allele was higher among Japanese (31%) than Whites (11-12%) and Blacks (3%), serum uric acid levels and gout prevalence were much lower in this Japanese sample. Traditionally, gout was rarely observed among Japanese people before the 1960s. Since then, the prevalence of gout has rapidly increased [4] , presumably because of rapid changes in lifestyle after World War II. This phenomenon is commonly observed with complex diseases, where adverse environmental exposures are thought to act on genetically susceptible individuals. Our findings may suggest a potential gene-environment interaction in relation to gout/uric acid resulting in an increased incidence of gout. That is, some factors that are part of a traditional Japanese lifestyle may protect from gout despite the high prevalence of the risk allele among Japanese. This hypothesis is in line with the fact that US Asians have almost three times the prevalence of diagnosed gout than US Whites [10] , since US Asians might be exposed to both a high prevalence of the risk allele and US lifestyle.
A limitation of this study is that we used the information of gout ascertained by a face-to-face interview. To our knowledge, no study has reported sensitivity, specificity or positive predictive value for interview in the diagnosis of gout based on a golden standard of clinical diagnosis. Another limitation is the moderate statistical power ($50-60%); since we found a positive association, this would not have affected the results materially. Thirdly, the usage of the OR might not be appropriate as an approximate of relative risk in cross-sectional study, because gout and hyperuricaemia are not scarce in general Japanese population, although rarer than in the USA or Europe (Table 1) . However, when we used an unadjusted prevalence ratio instead, the results did not change materially. Finally, we found in men that the uric acid level was lower among TT than TG carriers; this was probably due to small sample size in the TT stratum (n = 158).
A recent functional and association study of Japanese people [8] has identified another causal SNP of ABCG2, Q126X, with less frequency of minor allele (1.8% among control), but stronger effect on gout/hyperuricaemia than presently analysed ABCG2 (Q141K). A combination of these two SNPs may better predict gout/hyperuricaemia in the Japanese, which needs to be replicated in community-based samples.
In conclusion, the T allele at rs2231142 in ABCG2 was associated with higher serum uric acid levels and gout prevalence among Japanese patients, consistent with the previous results from Whites and Blacks. The high frequency of this established causal variant among Japanese people may have important implications for gout prevalence as more Japanese people adopt a Western lifestyle. Persons missing covariates were eliminated from the multivariable-adjusted analyses (n = 9 excluded). Gout was defined as a history of symptoms and/or past or present treatment of gout.
d Hyperuricaemia was defined as uric acid of 5415.9 mmol/l (7.0 mg/dl) and/or treatment of hyperuricaemia.
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. ABCG2 rs2231142 polymorphism was associated with higher uric acid levels and gout prevalence among Japanese. . The frequent causal variant, but the lower gout prevalence could be explained by their lifestyle.
